United States: WilmerHale Reps Editas Medicine In $94.4 Million IPO
Last Updated: February 8 2016

WilmerHale represented Massachusetts-based gene editing company Editas Medicine in its $94.4 million initial public offering, which occurred on February 2, 2016. The IPO was the first in the US in 2016.

The WilmerHale team on the transaction was led by Partners Steven D. Singer and Rosemary G. Reilly and included Counsel Jeffries Oliver-Li, and Associates Britt Eichner and Brett Bromann (corporate); as well as Partner Kim Wethly and Counsel Ciara Baker (tax). 

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Raya Treiser, Rob Lehman
By Gary Born
By Leila Gaafar
By Timothy Silva, Seth Davis
By Christopher Babbitt, Jonathan Bressler, Claire Chung
By WilmerHale
By Jonathan Yarowsky, Perry A. Lange, Hartmut Schneider, Leon Greenfield, D. Reed Freeman, Jr., Heather Zachary
By Jay Holtmeier, Erin Sloane
By Geoffroy Barthet, Nicole Callan, Cormac O'Daly, Hartmut Schneider
By WilmerHale
Tools
Print
Font Size:
Translation
Channels